Dylan Bram Crotty Sells 441 Shares of Stryker (NYSE:SYK) Stock

Key Points

• Stryker insider Dylan Bram Crotty sold 441 shares at an average price of $328.61, receiving $144,917.01 and reducing his holdings by 6.74% to 6,102 shares.
• Stryker’s latest quarterly results exceeded expectations, with adjusted EPS of $3.69 versus the $3.49 consensus and revenue of $6.59 billion, up 9.4% year over year.
• The company declared a quarterly dividend of $0.88 per share, equivalent to an annualized $3.52 payout and a 1.1% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $386.28.

Stryker Corporation (NYSE:SYK - Get Free Report) insider Dylan Bram Crotty sold 441 shares of the company's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Stryker Stock Down 0.2%

NYSE:SYK traded down $0.51 on Wednesday, reaching $330.08. 1,571,356 shares of the stock traded hands, compared to its average volume of 2,364,547. The company has a market capitalization of $126.61 billion, a price-to-earnings ratio of 34.21, a PEG ratio of 2.09 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company's fifty day simple moving average is $327.80 and its 200 day simple moving average is $331.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company's revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's payout ratio is presently 36.48%.

Hedge Funds Weigh In On Stryker

Large investors have recently modified their holdings of the stock. Brighton Jones LLC lifted its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new position in shares of Stryker during the second quarter valued at $205,000. Marshall Wace LLP increased its stake in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock valued at $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC bought a new stake in shares of Stryker in the second quarter valued at about $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker in the second quarter worth about $253,000. Institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. Piper Sandler dropped their target price on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. BTIG Research cut their target price on Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Stryker currently has a consensus rating of "Moderate Buy" and an average price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source